Compositions and methods for treatment of short telomere disorders

• US 10,046,007 B2
• Filed: 06/24/2016
• Issued: 08/14/2018
• Est. Priority Date: 06/24/2015
• Status: Active Grant

• Current Assignee: Kenneth M. Reed
• Original Assignee: Prescient Pharma, LLC
• Inventors: Idelevich, Pavel, Wang, Yanming
• Primary Examiner(s): Pallay, Michael B.
• Application Number:
  US15/192,557
• Publication Number:
  US 20160375052A1
• Time in Patent Office: 781 Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy

Abstract

The invention generally relates to methods of treating short telomere disorders using known compounds and pharmaceutical compositions comprising same. More specifically, the disclosed methods comprise, in one aspect, the step of administering to the subject an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, thereby treating the subject for the short telomere disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims

1. A method for treating idiopathic pulmonary fibrosis (IPF), the method comprising the step of administering to a subject an effective amount of at least one lithium compound selected from lithium chloride, lithium bromide, lithium carbonate, lithium nitrate, lithium sulfate, lithium acetate, lithium lactate, lithium citrate, lithium aspartate, lithium gluconate, lithium malate, lithium ascorbate, lithium orotate, lithium succinate, and combinations thereof, or a pharmaceutically acceptable salt thereof, thereby treating the subject for idiopathic pulmonary fibrosis (IPF).

2. The method of claim 1, wherein the subject is a mammal.

3. The method of claim 1, wherein the subject has been diagnosed with a telomere dysfunction prior to the administering step.

4. The method of claim 3, wherein the dysfunction is decreased cell signaling resulting in telomere shortening.

5. The method of claim 1, wherein the effective amount is a therapeutically effective or prophylactically effective amount.

6. The method of claim 5, wherein the effective amount is a therapeutically effective amount.

7. The method of claim 1, further comprising the step of identifying a subject in need of treatment of idiopathic pulmonary fibrosis (IPF).

8. The method of claim 1, wherein administration is by inhalation.

9. A method for the treatment of a subject comprising the steps of:

a. diagnosing the subject as having idiopathic pulmonary fibrosis (IPF); and

b. administering to the subject an effective amount of at least one lithium compound selected from lithium chloride, lithium bromide, lithium carbonate, lithium nitrate, lithium sulfate, lithium acetate, lithium lactate, lithium citrate, lithium aspartate, lithium gluconate, lithium malate, lithium ascorbate, lithium orotate, lithium succinate, and combinations thereof, or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein diagnosing comprises performing an experiment upon the subject and identifying a level of a biological marker.

11. The method of claim 10, wherein the biological marker is telomere length.

12. The method of claim 11, wherein the subject has been diagnosed with a telomere dysfunction prior to the administering step.

13. The method of claim 12, wherein the dysfunction is decreased cell signaling resulting in telomere shortening.

14. The method of claim 9, wherein administration is by inhalation.

15. The method of claim 9, the effective amount is a therapeutically effective or prophylactically effective amount.